This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB05806/identifier/wikipedia/
n6http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB05806/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB05806/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05806/identifier/chemspider/

Statements

Subject Item
n2:DB05806
rdf:type
n3:Drug
n3:description
BNP1350 is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
n3:generalReferences
# Thompson PA, Berg SL, Aleksic A, Kerr JZ, McGuffey L, Dauser R, Nuchtern JG, Hausheer F, Blaney SM: Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jun;53(6):527-32. Epub 2004 Mar 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14997342 # Yin MB, Guo B, Vanhoefer U, Azrak RG, Minderman H, Frank C, Wrzosek C, Slocum HK, Rustum YM: Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol. 2000 Mar;57(3):453-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10692484 # Van Hattum AH, Pinedo HM, Schluper HM, Hausheer FH, Boven E: New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer. 2000 Oct 15;88(2):260-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11004678
n3:group
investigational
n3:indication
Investigated for use/treatment in brain cancer, lung cancer, and melanoma.
owl:sameAs
n6:DB05806
dcterms:title
BNP 1350
adms:identifier
n9:130651 n10:DB05806 n11:148202 n12:Camptothecin
n3:mechanismOfAction
BNP1350, 7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, is a novel semi-synthetic, highly lipophilic, silicon-containing camptothecin and an inhibitor of topoisomerase I. It has been supercomputer engineered for superior oral bioavailability, superior lactone stability, broad anti-tumor activity, increased potency and insensitivity to Pgp/MRP/LRP drug resistance.
n3:synonym
Karenitecin
n3:IUPAC-Name
n4:271B470F-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4715-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4714-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4711-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4712-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4713-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B470D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B470B-363D-11E5-9242-09173F13E4C5 n4:271B470E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B470C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B471B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B471C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4716-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4717-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4719-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4718-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B471A-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4721-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4723-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4724-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4720-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B471F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4722-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4710-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B471D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B471E-363D-11E5-9242-09173F13E4C5